To investigate the effect of R on ddI kinetics and the safety of the combination, 12 patients maintained on ddI (167 or 250 mg twice daily) received ddI in the morning of day 1. On days 2 to 13, they received once daily R (300 mg/day, 8 patients; 600 mg/day, 4 patients) with their twice daily doses of ddI. On days 1 and 13, thirteen blood samples were obtained over 12 hours for ddI measurement (HPLC). Mean (+/-SD) ddI kinetic parameters for 11 patients are presented (table: see text). R did not affect ddI pharmacokinetics (p greater than 0.05 for all comparisons; 97 percent power to detect a 20 percent change in AUC). No changes in ECGs or electrolytes were noted during the study. Coadministration of R and ddI will not necessitate changes in ddI dose in symptomatic HIV infected patients.

Body Composition Body Weight Human Male Zidovudine/*PHARMACOKINETICS ABSTRACT

www.aegis.org